Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 36Terminated 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Thoracic 1CNS 1

Conditions

Breast Neoplasms 2Neoplasms 1Lung Neoplasms 1Glioma 1Disease Progression 1Brain Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Interventional × enzastaurin × Clear all
NCT00538681 2020-11-05

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Eli Lilly and Company

Phase 2 Terminated
35 enrolled 14 charts
Thoracic

Lung Neoplasms

NCT00536939 2020-09-24

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Eli Lilly and Company

Phase 2 Terminated
2 enrolled 5 charts
Breast

Breast Neoplasms

NCT00437294 2020-08-10

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Eli Lilly and Company

Phase 2 Terminated
86 enrolled 20 charts
Breast

Breast Neoplasms

NCT00108056 2019-12-05

Enzastaurin to Treat Recurrent Brain Tumor

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
26 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡